Impel Pharmaceuticals Inc investor relations material

Impel Pharmaceuticals Inc, develops therapies for patients with central nervous system diseases in the United States. The company is developing INP104 (dihydroergotamine mesylate), a drug candidate that is in Phase III clinical study for the treatment of cluster headache; and INP107 (sumatriptan) Nasal Powder, which has completed Phase I testing designed to investigate its safety, tolerability, pharmacokinetics, and delivery. Its product candidates are also developed for the treatment of migraine headache and pain associated with chronic sinusitis. The company was founded in 2015 and is headquartered in Seattle, Washington.